Literature DB >> 25362135

Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates.

Mudit Kulshrestha1, Martha Sola-Visner2, John A Widness3, Peter Veng-Pedersen4, Donald E Mager5.   

Abstract

Neonatal thrombocytopenia affects 22-35% of all neonates admitted to neonatal intensive care units. The purpose of this study was to develop a mathematical model for characterizing platelet (PLT) kinetics in thrombocytopenic preterm neonates. Immature PLT fraction (IPF) and PLT counts were measured for up to 35 days after birth in 27 very low birth weight preterm neonates. PLT transfusions were administered to 8 of the 27 (24%) subjects. The final model included a series of four transit compartments to mimic the production and survival of IPF and PLT. Model parameters were estimated using nonlinear mixed effects modeling with the maximum likelihood expectation maximization algorithm. The model adequately captured the diverse phenotypes expressed by individual subject profiles. Typical population survival values for IPF and PLT life spans in nonthrombocytopenic patients were estimated at 0.912 and 10.7 days, respectively. These values were significantly shorter in thrombocytopenic subjects, 0.429 and 2.56 days, respectively. The model was also used to evaluate the influence of growth and laboratory phlebotomy loss on the time course of IPF and PLT counts. Whereas incorporating body weight was essential to correct for expanding blood volume due to growth, phlebotomy loss, a possible covariate, did not significantly influence PLT kinetics. This study provides a platform for identifying potential covariates that influence the interindividual variability in model parameters regulating IPF and PLT kinetics and for evaluating future pharmacological therapies for treating thrombocytopenic neonates.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  immature platelet fraction; neonatal thrombocytopenia; platelets; transit compartment model

Mesh:

Year:  2014        PMID: 25362135      PMCID: PMC4281674          DOI: 10.1152/ajpheart.00528.2013

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  28 in total

1.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

2.  Automatic detection of immature platelets for decision making regarding platelet transfusion indications for pediatric patients.

Authors:  Katsuyasu Saigo; Yasuyuki Sakota; Yukako Masuda; Kyoko Matsunaga; Mariko Takenokuchi; Kunihiro Nishimura; Takeshi Sugimoto; Kosuke Sakurai; Makoto Hashimoto; Tomoko Yanai; Akira Hayakawa; Yasuhiro Takeshima; Tsutomu Nomura; Yoshitsugu Kubota; Shunichi Kumagai
Journal:  Transfus Apher Sci       Date:  2008-03-10       Impact factor: 1.764

3.  Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey.

Authors:  Cassandra D Josephson; Leon L Su; Robert D Christensen; Christopher D Hillyer; Marta-Inés Castillejo; Michele R Emory; Yulia Lin; Heather Hume; Kirk Easley; Brandon Poterjoy; Martha Sola-Visner
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

4.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

Review 5.  Neonatal thrombocytopenia and megakaryocytopoiesis.

Authors:  Francisca Ferrer-Marin; Zhi-Jian Liu; Ravi Gutti; Martha Sola-Visner
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

Review 6.  Megakaryocyte development and platelet production.

Authors:  Varda R Deutsch; Aaron Tomer
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

7.  Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?

Authors:  H Sallmon; R K Gutti; F Ferrer-Marin; Z-J Liu; M C Sola-Visner
Journal:  J Perinatol       Date:  2010-04-22       Impact factor: 2.521

8.  Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation and ERK signalling.

Authors:  Anatoly Samoylenko; Nadiya Byts; Krishnaraj Rajalingam; Nicolas von Ahsen; Ulf R Rapp; Hannelore Ehrenreich; Anna-Leena Sirén
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

Review 9.  Neonatal thrombocytopenia: what we do and don't know.

Authors:  Martha Sola-Visner; Matthew A Saxonhouse; Rachel E Brown
Journal:  Early Hum Dev       Date:  2008-08-05       Impact factor: 2.079

10.  Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.

Authors:  Kevin J Freise; John A Widness; Peter Veng-Pedersen
Journal:  J Pharmacol Exp Ther       Date:  2009-10-06       Impact factor: 4.030

View more
  2 in total

Review 1.  Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants.

Authors:  Hannes Sallmon; Natalie Timme; Begüm Atasay; Ömer Erdeve; Georg Hansmann; Yogen Singh; Sven C Weber; Elaine L Shelton
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.418

2.  Time course of immature platelet count and its relation to thrombocytopenia and mortality in patients with sepsis.

Authors:  Kansuke Koyama; Shinshu Katayama; Tomohiro Muronoi; Ken Tonai; Yuya Goto; Toshitaka Koinuma; Jun Shima; Shin Nunomiya
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.